Market Place
Sourcing Support
Allarity`s Ph2 Stenoparib Lung Cancer Trial Fully Funded By VA
06 Mar 2025 //
GLOBENEWSWIRE
Allarity to Start Phase 2 for Stenoparib in Ovarian Cancer
24 Feb 2025 //
GLOBENEWSWIRE
Allarity Adds Leaders To Advance Stenoparib PARP Program
03 Oct 2024 //
GLOBENEWSWIRE
Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer
25 Jun 2024 //
GLOBENEWSWIRE
Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance
14 May 2024 //
GLOBENEWSWIRE
Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone
02 May 2024 //
GLOBENEWSWIRE
Allarity Strategic Focus on Accelerating Stenoparib Toward Regulatory Approval
27 Mar 2024 //
GLOBENEWSWIRE
Allarity`s Phase 2 Stenoparib Data Indicates Clinical Benefit in Ovarian Cancer
05 Dec 2023 //
GLOBENEWSWIRE
Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib
20 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.